About us. The Institute Today
The Institute of Biotechnology and Antibiotics (IBA) is a state-owned research and development organization established in 1985 by the Minister of Industry. The IBA operates in the health service and pharmaceutical sector. It employs 151 people, including 34 research scientists.
The IBA’s mission is to:
- conduct scientific research in biotechnology, and the development and implementation of antibiotic technology and other biologically active substances
- umacnianie obrazu i pozycji Instytutu w środowisku naukowym i na rynku farmaceutycznymbuild up and elevate the image and position of the IBA within the scientific communities and in the pharmaceutical sector
- disseminate the quality assurance policy for IBA operations
The mission is carried out through:
- scientific works and research
- implementation of developed technologies through into production
- production based on in-house technology
- services contracted by external institutions
The Institute contributes to the achievements of Polish science in the following two fields:
- pharmaceutical biotechnology: genetic engineering of new gene expression systems, genome diagnostics, monoclonal antibodies and the production of highly purified biologically active compounds and protein structures (e.g. recombined human insulin, growth hormone, interferon)
- chemistry of therapeutic compounds, including research and production methods for ß-lactam, aminoglycosides, macrolide and anthracycline antibiotics.
IBA works together with a number of domestic and foreign scientific establishments and other companies in the pharmaceutical and medical industries.
The Institute has created three major antineoplastic drugs:
- Biorubina® (doxorubicin) - An anthracycline antibiotic used in the treatment of solid tumours: breast carcinoma, pulmonary carcinoma, urinary bladder carcinoma, thyroid carcinoma, ovarian carcinoma, sarcomas and haematological and lymphatic malignancies.
- Bioepicyna® (epirubicin) - An anthracycline antibiotic used in the treatment of a number of malignancies (inter alia breast carcinoma, ovarian carcinoma, pulmonary carcinoma and soft tissue sarcomas) primarily as a component of multidrug chemotherapy.
- Biodribin® (cladribine) - A deoxyadenosine nucleoside derivative used in hairy cell leukaemia, chronic lymphocytic
leukaemia and malignant non-Hodgkin’s lymphomas.
